Iqvia Holdings, Inc. · NYSE:IQV
Iqvia — IQVIA Research Forum 2022
51 slides from Iqvia's conference presentation, October 2022
Slide 1: IQVIA Research Forum 2022: Pathways and Priorities for High Impact Health Research
IQVIA Research Forum 2022 P a t h w a ys a n d P r i o r i t i e s f o r H i g h I m p a c t Health Research October 2022 Copyright © 2019 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.
Slide 2: IQVIA Institute for Human Data Science contributes to advancing human health
IQVIA Institute for Human Data Science contributes to advancing human health by generating rigorous, evidence-based research PROPRIETARY DATA SOURCES* LIBRARY OF REPORTS EVIDENCE- SUBJECT MATTER EXPERTS BASED RESEARCH CONFERENCES ADVANCED ANALYTICAL SKILLS AND FORUMS THIRD PARTY INFORMATION PEER-REV
Slide 3: Support for academic researchers
Support for academic researchers How researchers can benefit from IQVIA data IQVIA data assets frequently used in academic research Through collaboration with the IQVIA Institute, Formulary Impact Analyzer: Pharmacy claims with insight into paid, rejected researchers have access to a broad range of
Slide 4: Pathways and Priorities for High Impact Health Research
Pathways and Priorities for High Impact Health Research IQVIA Research Forum 2022 Incorporating Navigating the Exploring the Elevating the the impact of complexity elusive nature value to Charting the social and of applied heterogeneity patients of future of high determinants research in of patient
Slide 5: Elevating the value to patients of academic health research
Elevating the value to patients of academic health research 4
Slide 6: Panelists
Panelists Christian Reich, MD Professor of the Practice, Visiting Scientist, OHDSI The Roux Institute, Northeastern University Joseph (Joe) Ross, MD, MHS Co-founder MedRxiv Moderator: Murray Aitken, Executive Director, IQVIA Institute 5
Slide 7: How Do We Determine Whether Academic Research Brings Value to Patients?
How Do We Determine Whether Academic Research Brings Value to Patients? Research Endpoints Outcomes Decision-making Actions design Are the defined clinical Are the outcomes of the study Which shared decisions Which actionable clinical endpoints of the study meaningful and relevant to between patient
Slide 8: Volume of Health Research Growing Rapidly Year over Year
Volume of Health Research Growing Rapidly Year over Year PubMed Annual Rate of Published “Studies” 1970 - 2022 Studies 15,020,024 results 1,000,000 900,000 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 0 7 Source: PubMed, October 3, 2022
Slide 9: Higher Growth Areas of Research are Reflecting Current Issues
Higher Growth Areas of Research are Reflecting Current Issues Publications in 2022 Indexed to 2012 Total Publication Share by Thematic Area Publications 500 (thousands) 38 5 1 9 17 11 8 18 25 12 137 84 10 72 4 450 Indexed to 100 = Thematic Publication Share in 2012 400 350 300 250 200 150 Thematic A
Slide 10: Medical Research Tends to Focus More on Processes than Outcomes
Medical Research Tends to Focus More on Processes than Outcomes An analysis of the impacts described in 162 case studies submitted from community-based health sciences as part of the 2014 Research Excellence Framework. The majority described changes in processes rather than outcomes Source: Richard
Slide 11: Patient Perspectives on Gaps in Health Research
Patient Perspectives on Gaps in Health Research “Everybody claims to have patient-relevant The C.D.C. found that record numbers of children under 5 had been endpoints, but they are not always based on hospitalized during the Omicron surge, underscoring the need for vaccines. science and they are not
Slide 12: Potential Sources of Leakage in Health Research Patient Value
Potential Sources of “Leakage” in Health Research Patient Value Where are the gaps in the evidence chain? Patient expertise Medical journal Medical journal editors don’t always engage Enabling process patient-experts in the Novel research technologies The medical journal review of studies. publicati
Slide 13: New Pathway for Elevating Value of Research to Patients
New Pathway for Elevating Value of Research to Patients Employ patient-reviewers Employing experts in patient and real-world issues in the editorial review process Co-design research with Develop measurement people affected guidelines Bringing in people who are Developing consensus guidelines affect
Slide 14: OHDSI Overview
OHDSI Overview Christian Reich
Slide 15: What OHDSI is: Open Source, Community, Data
What OHDSI is: Ambulatory Hospital ✓ Open Source ✓ Community ✓ Data Why Choose OHDSI/OMOP: ✓ Fast, reliable studies across a series of datasets and data types ✓ Reduced cost of ownership including understanding coding schemes, writing statistical programs across OHDSI Collaborators: OHDSI Network: d
Slide 16: How OMOP Works
How OMOP Works
Slide 17: Current Approach: One Study – One Script
Current Approach: “One Study – One Script“ "What's the adherence to my drug in the data assets I own?" Analytical method: North America China Adherence to Drug Southeast Asia Japan Europe UK India Application to Switzerland Italy South Africa Israel data Current solution: One SAS or R script • Not s
Slide 18: The OHDSI Approach
The OHDSI Approach Mortality Prediction Adherence North America Southeast Asia China Europe UK Japan India South Africa Switzerland Italy Israel Standardized Safety data Signals OHDSI Tools OMOP CDM
Slide 19: Analytics can be remote
Analytics can be remote North America Southeast Asia China Europe UK Japan India So Africa Switzerland Italy Israel
Slide 20: Analytics can be behind firewall
Analytics can be behind firewall
Slide 21: OHDSI Research Network
OHDSI Research Network EHR Structure and participants EHR EHR EHR Network Partner Network Partner Research Network Partner Network Partner institution Registry Statistical Programming Warehouse EHR Service No central EHR control EHR Claims Claims Network Partner Network Partner Network Partner Netwo
Slide 22: OHDSI Tools
OHDSI Tools
Slide 23: Opportunities for Standardization
Opportunities for Standardization Data structure tables, fields, data types Data content vocabulary to codify clinical domains Data semantics conventions about meaning Protocol Cohort definition algorithms for identifying the set of patients who meet a collection of criteria for a given interval of
Slide 24: Standard Content: OMOP Common Data Model
Standard Content: OMOP Common Data Model
Slide 25: Applications
Applications
Slide 26: Mapping regulatory use cases to evidence types
Mapping regulatory use cases to evidence types Questions that can be Design and feasibility of informed with real world Support the planning & validity of applicant studies planned studies evidence: Who are the patients with disease Clinical eligible for treatment? Representativeness and characteriz
Slide 27: Expanding the proactive use of real-world evidence for study planning and validity
Expanding the proactive use of real-world evidence for study planning and validity ~seconds Anticipatory ~minutes Prepared ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Support the planning & validity of applicant studies
Slide 28: Expanding the proactive use of real-world evidence for study planning and validity
Expanding the proactive use of real-world evidence for study planning and validity ~seconds Anticipatory ~minutes Prepared ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Support the planning & validity of applicant studies
Slide 29: Expanding the proactive use of real-world evidence for understanding clinical context
Expanding the proactive use of real-world evidence for understanding clinical context ~seconds Anticipatory 2026 ~minutes Prepared 2026 ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Understand clinical context https://data.ohdsi.org/Covid19Characterizat
Slide 30: Expanding the proactive use of real-world evidence for understanding clinical context
Expanding the proactive use of real-world evidence for understanding clinical context ~seconds Anticipatory 2026 ~minutes Prepared 2026 ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Understand clinical context
Slide 31: Expanding the proactive use of real-world evidence to investigate associations and impact
Expanding the proactive use of real-world evidence to investigate associations and impact ~seconds Anticipatory ~minutes Prepared 2026 ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Investigate associations and impact
Slide 32: Expanding the proactive use of real-world evidence to investigate associations and impact
Expanding the proactive use of real-world evidence to investigate associations and impact ~seconds Anticipatory ~minutes Prepared 2026 ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Investigate associations and impact
Slide 33: Expanding the proactive use of real-world evidence to investigate associations and impact
Expanding the proactive use of real-world evidence to investigate associations and impact ~seconds Anticipatory ~minutes Prepared 2026 ~hours Responsive 2026 ~days Enabled 2026 ~weeks, months, Reactive toda 2026 years Bespoke y Investigate associations and impact
Slide 34: Concluding thoughts
Concluding thoughts • Enabling use and establishing value of real-world evidence requires building trust across stakeholders – evidence generators and consumers • People and processes need to be augmented with science, technology and engineering –Research network = people + data + analytic tools + b
Slide 35: Program Details: Master of Science in Real World Evidence
Introducing the Master of Science in Real World Evidence in Healthcare and Life Sciences at Northeastern University Bouvé College of Health Sciences • Professional-level masters to upskill Program Details Location: Boston Campus, Online, Hybrid and meet the workforce demands of Commitment: Full-time
Slide 36: Ensuring Impact and Value of Medical Research to Patients
Ensuring Impact and Value of Medical Research to Patients IQVIA Research Forum October 12, 2022 Joseph S. Ross, MD, MHS Section of General Internal Medicine, Yale School of Medicine @jsross119 Associate Editor, The BMJ Co-Founder, medRxiv
Slide 37: Critical considerations for ensuring research impact and value to patients
Critical considerations for ensuring research impact and value to patients • Bring clinical experience to the table • Engage patients and policy makers to establish the research question • Publicly pre-specify study design, endpoints, methods • Timely and comprehensive results reporting • Translate
Slide 38: Publish/report the methods before the results!
Publish/report the methods before the results! Source: Ann Intern Med 2013;158:200-207. Sys Reviews 2015;4:1. BMJ 2021;372:m4856.
Slide 39: Timely and comprehensive results reporting
Timely and comprehensive results reporting • Research projects invariably deviate from the pre-specified study protocol and analysis plan – report everything that you said you would do that you did and explain everything that you did not! • Follow EQUATOR guidelines on research reporting • Clinical
Slide 40: Platform Policies and Potential Benefits
Platform Policies • Submission requirements that follow ICMJE guidance on author details, funding statements, ethical oversight, trial registration • Only original research articles and study protocols allowed • Screening by staff and affiliates before posting • Signals for caution Potential Benefit
Slide 41: medRxiv submission and posting statistics
~41k unique articles submitted ~34k unique articles posted ~83% posted ~185k unique authors ~155 countries ~21% revised ≥1x 56 (0.16%) withdrawn ~54% COVID-19 related
Slide 42: Community Engagement and Dissemination
Community Engagement and Dissemination • 8754 total user comments on preprints; 2352 (6.8%) have at least one. • 312 (1.1%) preprints with an Altmetric score >1000; median of 2 (IQR, 0-11) • Thus far, 13,361 (38.8%) preprints published in 2684 peer-reviewed journals (median interval of 153 days betw
Slide 43: Translate findings for patients
Translate findings for patients Source: BMJ 2022;377:e070603. JAMA Network Open 2022;5:e2217709. JAMA 2022;online first. BMJ 2020;370:m3379.
Slide 44: Strengthening Science through Data Sharing
Strengthening Science through Data Sharing • Ensures all data can be used to inform clinical decisions • Positions research as a public good • Respects contributions of participants: • maximizing value of collected data, while • minimizing duplicative data collection • Facilitates secondary studies
Slide 45: Q&A
Q&A Post your questions and comments in the Q&A box 44
Slide 46: Charting the future of high impact health research
Charting the future of high impact health research 45
Slide 47: Panelists
Panelists Caleb Alexander, MD, MS Professor Johns Hopkins Bloomberg School of Public Health Mui Van Zandt VP&GM Real World Data & Tech IQVIA Murray Aitken Executive Director IQVIA Institute for Human Data Science Moderator: Stig Albinus, Senior Advisor, IQVIA Institute for Human Data Science 46
Slide 48: Charting the Future with High Impact Health Research
Charting the Future with High Impact Health Research - Perspectives from the 2022 Research Forum High impact health research is delivered through: Advancing a multidisciplinary learning Navigating the complexity and health systems approach to national heterogeneity of patient health crises, balancin
Slide 49: 2022 Research Forum Agenda
2022 Research Forum Agenda Incorporating Navigating the Exploring the Elevating the the impact of complexity elusive nature value to Charting the social and of applied heterogeneity patients of future of high determinants research in of patient academic impact health on outcomes national health affo
Slide 50: Download featured Institute content
Download featured Institute content www.IQVIAInstitute.org Find us on social media Twitter: @IQVIA_Institute LinkedIn: #IQVIAInstitute 49
Slide 51: Thank you
Thank you Global Trends in R&D: Overview through 2020. Report by the IQVIA Institute for Human Data Science.